Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Average Price Target from Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.2333.

Several analysts have commented on the company. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wall Street Zen downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Finally, Weiss Ratings lowered Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, September 4th.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD opened at $4.53 on Friday. The firm has a market cap of $748.54 million, a PE ratio of 5.88 and a beta of 0.20. Ironwood Pharmaceuticals has a one year low of $1.26 and a one year high of $5.78. The firm’s fifty day moving average is $4.14 and its two-hundred day moving average is $3.91.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The business had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. Research analysts predict that Ironwood Pharmaceuticals will post 1.1 earnings per share for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider directly owned 313,680 shares in the company, valued at $1,417,833.60. This trade represents a 28.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently bought and sold shares of IRWD. Krilogy Financial LLC raised its position in shares of Ironwood Pharmaceuticals by 9.8% in the 1st quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,971 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Ironwood Pharmaceuticals by 9.6% during the fourth quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock worth $122,000 after buying an additional 3,170 shares in the last quarter. DGS Capital Management LLC grew its position in shares of Ironwood Pharmaceuticals by 42.8% during the first quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,458 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Ironwood Pharmaceuticals by 26.8% during the first quarter. Hsbc Holdings PLC now owns 29,706 shares of the biotechnology company’s stock worth $104,000 after buying an additional 6,270 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Ironwood Pharmaceuticals by 48.7% in the first quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock worth $71,000 after buying an additional 6,656 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.

Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.